Pharma major, Lupin Ltd., announced today that its subsidiary Lupin Pharmaceuticals Inc. has received final approval for its Escitalopram tablets (Escitalopram oxalate) 5 mg, 10 mg, and 20 mg strengths from the United States Food and Drugs Administration (FDA) to market a generic version of Forest Laboratories, Inc.’s (Forest) Lexapro® Tablets, 5 mg, 10 mg, and 20 mg, the company informed in a press statement on the Bombay Stock Exchange.
Lupin claimed its Escitalopram tablets is the AB-rated generic equivalent of Forest's Lexapro® tablets and is indicated for acute and maintenance treatment of major depressive disorder in adults and adolescents aged 12- 7 years. It is also indicated for the acute treatment of general anxiety disorder in adults.
Lexapro® Tablets had annual U.S sales of approximately $2.7 billion for the twelve months ending June, 2012
